The EPS miss against consensus is notable, but strong revenue growth, expanding margins, and robust cash flow may offset. Watch for full-year 2026 guidance update on the conference call and any further details on the Inland Psychiatric Medical Group collaboration.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $10.67entry
- T+1 · 6d ago +5.34%α +4.02% · $11.24
- T+4 · todayOpen
- T+5 · in 8h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
BrainsWay reported Q3 2026 revenue of $18.1M (+34% YoY) and diluted EPS of $0.05, below the consensus estimate of $0.09. Operating income rose 107% to $2.6M, and adjusted EBITDA grew 92% to $3.9M. The company guided full-year 2026 results to the upper end of prior ranges with potential to modestly exceed.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $18.1M vs $13.5M in Q3 2025, +34% YoY
- Diluted EPS $0.05 vs consensus $0.09 (miss of 44%)
- Operating income $2.6M, +107% YoY; margin expanded to 14% from 9%
- Adjusted EBITDA $3.9M, +92% YoY; margin expanded to 21% from 15%
- Net income $2.2M, +42% YoY
- RPOs $85M, +31% YoY
- Shipped 130 Deep TMS systems, +44% YoY; installed base ~2,080 systems
- Operating cash flow $6.2M in Q3 2026
- Full-year 2026 guidance: results expected at upper end of prior ranges, potential to modestly exceed
Financial Impact
Revenue $18.1M (+34% YoY), diluted EPS $0.05 (consensus $0.09), operating income $2.6M (+107% YoY), adjusted EBITDA $3.9M (+92% YoY)
Risk Factors
- EPS miss of 44% vs consensus may pressure the stock near term
- Full-year guidance language is qualitative (upper end of range) with no specific numbers
- Cash and equivalents declined to $30.1M from $67.7M at year-end 2025, partly due to $33M short-term deposit investment
- Deep TMS not FDA cleared for suicidal ideation or Alzheimer's, limiting clinical data commercial value
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-007310 |
| Document: f6k_110926.htm | 0001171843-26-007310 |
| Document: 0001171843-26-007310-index-headers.html | 0001171843-26-007310 |
| Document: 0001171843-26-007310-index.html | 0001171843-26-007310 |
| Document: 0001171843-26-007310.txt | 0001171843-26-007310 |
| Earnings Context (Synthetic; results releases only) | 0001171843-26-007310 |
Track record
24 reports on BWAY
6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +27.55% at T+60 after the Mar 4, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Bullish 6/10 No price data
- Nov 10, 20266d ago 6-K Neutral 5/10 Viewing Entry $10.67 Now $9.39 −12.00% settles Dec 9
- Nov 2, 202614d ago 6-K Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
- Oct 26, 202621d ago 6-K Neutral 3/10 Entry $11.21 Now $9.39 −16.24% settles Nov 23
- Oct 21, 202626d ago 6-K Neutral 3/10 Entry $11.44 Now $9.39 −17.92% settles Nov 19
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $11.99 to $9.39 Now $9.39 −21.68% ▼ −21.68% −18.22% vs SPY
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $11.99 to $9.39 Now $9.39 −21.68% ▼ −21.68% −18.22% vs SPY
- Oct 13, 20264w ago 6-K Neutral 4/10 Entry $11.92 to $10.67 Now $9.39 −21.22% ▼ −10.49% −6.88% vs SPY
- Sep 8, 20269w ago 6-K Neutral 4/10 Entry $14.16 to $11.89 Now $9.39 −33.69% ▼ −16.03% −18.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers